Semax

Semax is a synthetic peptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro (MEHFPGP), derived from the 4-7 fragment of adrenocorticotropic hormone (ACTH). It was developed by the Institute of Molecular Genetics of the Russian Academy of Sciences in the 1980s as part of an ACTH analog research program.

Unlike ACTH, Semax does not stimulate cortisol production and lacks the hormonal side effects of the parent molecule. Researchers found that the 4-7 fragment retained significant neurotrophic and cognitive-enhancing properties while being free of the adrenal stimulation that makes ACTH itself unsuitable for cognitive applications.

Semax is registered as a prescription drug in Russia and Ukraine, where it is used medically for stroke treatment and recovery, cognitive impairment, ADHD-like conditions, peptic ulcers, optic nerve disorders, and anxiolytic (anti-anxiety) applications. This registered drug status provides a higher level of regulatory and clinical validation than is typical for peptides used in Western research communities.

Semax is typically administered as a nasal spray, which allows it to bypass the blood-brain barrier through olfactory pathways and achieve direct central nervous system effects without injection. This non-injectable route makes it more accessible for research purposes. It is not FDA-approved in the United States.

Semax exerts its effects through several complementary neurological mechanisms:

• BDNF upregulation: Semax dramatically increases brain-derived neurotrophic factor (BDNF) expression in the hippocampus and prefrontal cortex — two regions critical for learning, memory, and higher cognition. BDNF is essential for neuronal survival, synaptic plasticity, and long-term potentiation (LTP), which underpins memory formation.
• NGF stimulation: Nerve growth factor (NGF) expression is also upregulated, supporting neuronal health and cholinergic neurotransmission important for attention and memory.
• Dopaminergic system modulation: Semax influences dopamine receptor sensitivity and dopamine metabolism, which may contribute to its effects on motivation, focus, and mood.
• Serotonergic effects: Modulation of serotonin signaling contributes to anxiolytic effects and emotional regulation.
• Neuroprotection: Semax protects neurons against ischemia, oxidative stress, and excitotoxicity, partly through upregulation of antioxidant enzymes and stabilization of mitochondrial function in neurons.
• Anti-inflammatory CNS effects: Semax modulates microglial activation and reduces neuroinflammation, which is relevant to cognitive impairment and neurodegenerative disease.
• Melanocortin receptor activity: As an ACTH-derived peptide, Semax interacts with melanocortin receptors (MC4R and MC3R) in the CNS, which are involved in learning, attention, and stress responses.

Semax benefits are supported by both clinical (Russian/Ukrainian) and preclinical research:

• Cognitive enhancement: Clinical trials in Russia report improved memory, attention, and learning speed in healthy subjects and cognitive impairment patients, with effects beginning within hours to days of administration.
• Stroke recovery: Semax is clinically used in Russia for ischemic stroke treatment. Studies report improved neurological outcomes, reduced infarct size, and faster functional recovery with early post-stroke Semax administration.
• Anxiolytic effects: Both clinical reports and animal studies show anxiolytic (anti-anxiety) effects, which may be related to serotonergic and dopaminergic modulation.
• ADHD-like symptom improvement: Clinical reports from Russia describe improved attention and impulse control in children and adults, possibly through dopaminergic effects.
• Optic nerve neuroprotection: Used clinically in Russia for optic nerve disorders, with published studies showing preserved visual function in glaucoma and ischemic optic neuropathy models.
• Stress resilience: Research in stress models shows Semax reduces stress-induced cognitive impairment and behavioral changes, possibly through BDNF and glucocorticoid receptor modulation.

Semax has an established safety record in Russian clinical use spanning decades. Common and notable side effects include:

• Nasal irritation: The most common side effect with intranasal administration; typically mild and transient
• Initial headache: Some users report headaches with initial dosing, which often resolve with continued use
• Stimulation/insomnia: As a cognitive stimulant, Semax can cause difficulty sleeping if taken too late in the day
• Anxiety increase: Paradoxically, some individuals report increased anxiety particularly at higher doses, possibly due to dopaminergic overstimulation
• Appetite changes: Reduced appetite has been reported anecdotally

Long-term safety data from Russian clinical use suggests a generally favorable profile. No serious adverse events were identified in published clinical trials. As with any neurologically active agent, individual variation in response is significant, and psychiatric history may affect tolerability.

Disclaimer: Semax is not FDA-approved in the US. The following references Russian clinical and research protocols.

Semax is typically administered intranasally:

• Standard cognitive dose: 200–900 mcg per day (1–3 sprays per nostril with typical Russian 0.1% formulations)
• Clinical stroke protocol: Higher doses (1–3 mg/day) used in acute stroke contexts in Russian clinical settings
• N-Acetyl Semax (NA-Semax): A modified version with an N-terminal acetyl group and reported extended action and enhanced potency
• N-Acetyl Semax Amidate (NASSA): Further modified form with both N-acetyl and C-terminal amide modifications, reported to have even longer activity
• Cycle length: Typical research protocols range from 10–14 day courses with breaks, though some use continuously

The nasal route bypasses first-pass metabolism and may directly access the CNS via the olfactory pathway. Proper nasal spray administration technique affects efficacy.

Semax has a more robust clinical literature than most peptides used in the Western research community, owing to its registered drug status in Russia:

• Stroke trials: Multiple Russian clinical trials support Semax use in ischemic stroke. A notable multicenter trial (Gusev et al.) showed significantly improved neurological recovery scores and reduced disability in stroke patients receiving Semax versus placebo.
• BDNF research: Studies by Dolotov, Levitskaya, and colleagues have characterized the BDNF and NGF upregulation mechanism, providing a compelling mechanistic basis for Semax's cognitive effects.
• Animal cognition models: Extensive preclinical studies in learning and memory paradigms (Morris water maze, novel object recognition) show consistent cognitive enhancement effects.
• Optic nerve studies: Clinical research supports Semax use for optic nerve ischemia, with improvements in electroretinogram (ERG) parameters and visual acuity.

Limitations: Most clinical research was conducted in Russia with varying methodological rigor by Western standards. Independent replication and Western regulatory-standard clinical trials are lacking. Translation to diverse non-Russian populations has not been assessed in controlled studies.